Trial Profile
Efficacy of First Line Bortezomib, Rituximab, Ibrutinib (B-RI) for Patients With Treatment Naive Waldenström's Macroglobulinemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Ibrutinib (Primary) ; Rituximab (Primary) ; Rituximab (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 07 Mar 2022 Planned primary completion date changed from 1 Mar 2022 to 1 Dec 2022.
- 06 Dec 2021 Status changed from recruiting to active, no longer recruiting.
- 01 Oct 2019 Planned End Date changed from 1 Nov 2024 to 1 Sep 2029.